InspireMD reports revenue increase but net loss, plans US launch for CGuard Prime

From Investing.com: 2024-08-11 13:05:05

InspireMD reported a revenue increase of 5.4% in Q2 2024, earning $1.74 million. Gross profit decreased by 32.6% and operating expenses rose by 48%, resulting in a net loss of $7.9 million for the quarter. The company is focused on launching CGuard Prime in the US market in the first half of 2025, following positive outcomes data for the CGuard Carotid Stent System.Key Takeaways: InspireMD faces challenges with decreased gross profit and increased operating expenses, leading to a net loss for the quarter. Despite this, the company is optimistic about its future with plans to launch CGuard Prime in the US market and positive feedback from physicians on the CGuard Stent System. InspireMD is investing in clinical trials and product development to drive revenue growth potential in the coming years.



Read more at Investing.com: InspireMD reports growth and anticipates US launch By Investing.com